Erasca Inc is a trailblazing biopharmaceutical company dedicated to defeating cancer. With a sharp focus on RAS/MAPK pathway-driven cancers, Erasca is advancing a promising pipeline of potential therapies. Its leading candidates, ERAS-007 and ERAS-601, target various cancers including lung, colorectal, and acute myeloid leukemia, as well as advanced solid tumors. Additionally, Erasca is developing ERAS-801 for recurrent brain cancer. Founded in 2018, this San Diego-based company is on a mission to transform cancer treatment.
Clinical-stage biotech is one of the few corners of the market where a sub-$30 share price genuinely matters: small-cap oncology names can re-rate violently around a single Phase 3 readout or FDA…
Wall Street is turning constructive on three clinical-stage biotechs simultaneously, each sitting at the edge of a binary catalyst. The analyst calls on uniQure (NASDAQ:QURE), Syndax Pharmaceuticals (NASDAQ:SNDX), and Erasca (NASDAQ:ERAS) share…
A biotech stock rallying on encouraging trial results prompted insider buying and selling. A specialty retailer and others saw insider buying too.
